The FDA decision on Adamis Pharmaceuticals Corp.’s (ADMP) ZIMHI Injection, proposed for the reversal of opioid overdose, is expected on October 31, 2019.ZIMHI is a high dose Naloxone injection product candidate administered using a patented Symject device. Naloxone has been used as the standard treatment for opioid overdose for more than 45 years, and the current approved dose is only 2 mg. Given the fact that there are more potent opioids such as fentanyl, which are linked to high mortality, Adamis has proposed a novel high dose of Naloxone.The drug overdose epidemic is a public health crisis in the U.S. According to the CDC, there were over 72 thousand drug overdose-related deaths in 2017 with greater than 40% caused by synthetic opioids like fentanyl. According to IQVIA (IMS) National Sales Perspective, the addressable market opportunity for ZIMHI is estimated to be $330 million.In July of this year, Adamis settled all patent infringement cases filed by kaléo, a privately-held pharmaceutical company, related to ZIMHI.ADMP closed Friday’s (Sep.27, 2019) trading at $0.74, down 0.99%.